doi:10.3969/j.issn.1673-8640.2015.06.027

Abstract

CLC Number:

R446.1

Figures/Tables 1

References 9

[1]	中华人民共和国卫生部. 手足口病诊疗指南(2010版)[S].中华人民共和国卫生部,2010.
[2]	陈莎,王旭东,黄永国,等. 高敏心肌肌钙蛋白T、心肌酶与心电图在儿童手足口病感染中的应用[J]. 检验医学,2012,27(2):126-128.
[3]	李维春,王圣东. 心肌肌钙蛋白Ⅰ、高敏C反应蛋白检测在手足口病患儿心肌损伤中的临床价值[J].中国实验诊断学,2009,13(4):550-551.
[4]	单丽沈,刘春峰,袁壮,等.血清CRP在小儿感染性休克中临床意义的探讨[J].小儿急救医学,2004,11(2):84-85.
[5]	陈长强,顾志东,樊绮诗. 血清淀粉样蛋白A在疾病应用中的研究进展[J]. 检验医学,2012,27(9):776-779.
[6]	宋春华,穆云,马骏,等.血清淀粉样蛋白A与慢性疾病关系的研究进展[J].中华老年医学杂志,2011,30(9):788-790.
[7]	杨兰辉,苏艳丹,丁恒,等. C-反应蛋白和淀粉样蛋白A在手足口病诊疗中的应用研究[J]. 检验医学与临床,2012,9(22):2838-2839.
[8]	费凤英,衣萍,林见敏. 血清淀粉样蛋白A与C 反应蛋白联合检测的临床应用价值[J]. 检验医学,2014,29(10):1031-1033.
[9]	胡玲,张迎梅.血清前白蛋白和C-反应蛋白联合检测临床意义[J].医学理论与实践,2008,21(6):649-651.

组别	例数	hs-CRP	SAA	PA
手足口病组	126	8.63±2.44^*	187.63±86.89^*	163.71±24.22^*
普通组	113	7.32±2.39	116.75±36.89	189.32±29.25
危重组	13	18.60±5.83^#	523.33±106.35^#	135.38±20.27^#
正常对照组	60	4.35±1.22	6.55±1.87	235.43±33.15

组别	例数	hs-CRP	SAA	PA
手足口病组	126	8.63±2.44^*	187.63±86.89^*	163.71±24.22^*
普通组	113	7.32±2.39	116.75±36.89	189.32±29.25
危重组	13	18.60±5.83^#	523.33±106.35^#	135.38±20.27^#
正常对照组	60	4.35±1.22	6.55±1.87	235.43±33.15

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 9

Related Articles 15

Recommended Articles

Metrics